Why the study?
HFpEF has high heterogeneity, complex pathogenesis, limited clinical treatment, poor prognosis, and lacks specific guidelines for clinical practice despite recent research progress.
Answers are grounded in this paper and cite their sources.
This review summarizes recent progress in the pathogenesis and treatment of HFpEF to guide clinical practice.
Heart failure with preserved ejection fraction (HFpEF) is a special and common clinical heart failure with left ventricular diastolic dysfunction. It has attracted much attention at home and abroad in recent years because of its high heterogeneity and complex pathogenesis. Compared with heart failure with reduced ejection fraction (HFrEF), HFpEF has complex clinical manifestations, many complications, limited clinical treatment, and poor prognosis. In recent years, the research on the pathogenesis and treatment of HFpEF has made certain progress, but there are no specific guidelines for clinical practice. By combing the latest research at home and abroad, the pathogenesis and treatment of HFpEF are systematically reviewed in order to provide a relevant basis for reference its clinical treatment.
No takes yet. Share an insight, caveat, or question.
Song et al. (2021) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Heart failure therapies (Diuretics, ACEI/ARB, beta-blockers, SGLT2i, sacubitril-valsartan) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: